Current therapeutic approaches for cardiometabolic and obesity-related diseases often fail to address the underlying epigenetic dysregulation that contributes to disease progression. Existing methods lack the ability to comprehensively profile and target the epigenome at single-cell resolution, limiting the development of precision epigenetic medications.

Moonwalk Biosciences is developing precision epigenetic therapeutics by employing an end-to-end epigenetic discovery platform that profiles the epigenome at single-cell resolution. The platform leverages large-scale genome-wide profiling and perturbation studies to reveal causal relationships between the epigenome, genome, and gene expression. By identifying and modulating gene regulation through small molecules, oligonucleotide therapeutics, or direct editing strategies, Moonwalk aims to return cells to a healthy state. The company is advancing internal drug discovery programs focused on treating cardiometabolic and obesity-related diseases, with a focus on tissue specificity, gene regulation of brown/beige fat, energy dissipation, and metabolic dysfunction.

End-to-end epigenetic discovery platform capable of profiling the epigenome at the whole genome with single-cell resolution

AI-driven prediction of epigenetic targets

Broadest set of epigenetic engineering tools for perturbation

Epigenomic Foundation Model (EFM) to predict targets that can deterministically move cells from an initial state to a desired state

EpiRead technology for complete methylation maps of major T cell subsets

EpiWrite technology for multiplexed epigenome edits in primary human cells

Capabilities for other epigenomic modifications, such as histones

The primary target audience includes patients with cardiometabolic and obesity-related diseases, as well as pharmaceutical companies seeking solutions for biochemical pathways involving multiple genes.